Bürkert投资初创公司Green Elephant Biotech-动脉网

Bürkert invests in start-up Green Elephant Biotech

D-Pharm 等信源发布 2025-02-17 12:46



可切换为仅中文







Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies can work together to develop more efficient, flexible and sustainable cell cultivation processes in the pharmaceutical and biotech industries. This partnership should enable more cost-effective production of therapeutics and facilitate access to the latest biopharmaceutical trends..

Bürkert Fluid Control Systems作为战略投资者入股了Green Elephant Biotech，因此两家公司可以携手合作，在制药和生物技术行业开发更高效，灵活和可持续的细胞培养过程。这种伙伴关系应该能够更具成本效益地生产治疗药物，并促进获得最新的生物制药趋势。。

Family business invests in start-up

家族企业投资创业

As part of a strategic partnership, Bürkert Fluid Control Systems has taken a stake in the Giessen-based start-up Green Elephant Biotech. Together with Bürkert, the start-up is aiming to make cell cultivation processes in the pharmaceutical and biotech industries more efficient, flexible and sustainable so that, for example, life-saving therapeutics can be produced more cost-effectively.

作为战略合作伙伴关系的一部分，Bürkert流体控制系统公司已入股位于吉森的初创公司Green Elephant Biotech。与Bürkert一起，这家初创公司的目标是使制药和生物技术行业的细胞培养过程更加高效，灵活和可持续，从而可以更具成本效益地生产救生疗法。

The partnership gives Bürkert access to the latest trends and developments in the biopharmaceutical industry, one of the strategic core markets of the fluidics specialist from Ingelfingen. “We believe that Green Elephant Biotech’s innovative cell culture systems have great potential to revolutionise production processes in the industry.

该合作关系使Bürkert能够了解生物制药行业的最新趋势和发展，生物制药行业是Ingelfingen流体专家的战略核心市场之一。“我们相信，绿象生物技术的创新细胞培养系统具有巨大潜力，可以彻底改变该行业的生产流程。

This is in line with our corporate vision of bringing solutions for a regenerative economy to the market,” says Bürkert CEO Georg Stawowy..

这符合我们将再生经济解决方案推向市场的公司愿景，”Bürkert首席执行官GeorgStawowy说道。。

Green Elephant Biotech was founded in 2021 by Dr Joel Eichmann and Felix Wollenhaupt at the Technische Hochschule Mittelhessen University of Applied Sciences in Giessen. Compared to conventional cell culture vessels, the innovative and patented CellScrew® cell cultivation system enables a hugely increased growth surface for adherent cell cultures with the same volume.

绿象生物技术公司由Joel Eichmann博士和Felix Wollenhaupt于2021年在吉森的Technische Hochschule Mittelhessen应用科学大学成立。与传统的细胞培养容器相比，创新且获得专利的CellScrew®细胞培养系统可以大大增加相同体积的贴壁细胞培养物的生长表面。

Furthermore, the CellScrew® is additively manufactured from polylactide (PLA) using 3D printing..

此外，CellScrew®是使用3D打印由聚乳酸（PLA）附加制造的。。

Founder Felix Wollenhaupt explains: “Conventional cell culture vessels are significantly larger, are single-use items, are thrown away after one use and are often incinerated for regulatory reasons. This produces a lot of CO2. Our CellScrew® is, firstly, made from less raw material, which means less waste in and of itself.

创始人Felix Wollenhaupt解释说：“传统的细胞培养容器要大得多，是一次性使用的物品，一次使用后就会扔掉，并且由于监管原因经常被焚烧。这会产生大量的二氧化碳。首先，我们的CellScrew®由更少的原材料制成，这意味着其本身和自身的浪费更少。

Secondly, we use PLA, a biopolymer obtained from plants. This reduces the carbon footprint by around 90 % compared to conventional systems.”.

其次，我们使用PLA，一种从植物中获得的生物聚合物。。

By working with Bürkert as a strong, strategic partner, the founders have access to resources that will enable them to further develop their company. Joel Eichmann adds: “Together with Bürkert, we want to turn the CellScrew® into a fully fledged bioreactor. This requires liquids to be exchanged, gases to be monitored and processes to be regulated.

通过与Bürkert作为强大的战略合作伙伴合作，创始人可以获得资源，使他们能够进一步发展公司。Joel Eichmann补充道：“我们希望与Bürkert一起将CellScrew®转变为一个成熟的生物反应器。这需要交换液体，监测气体，并对过程进行监管。

Bürkert has the technical components and expertise to integrate this into a system. Together, we want to develop a cost-effective, reliable and sustainable production platform for the pharmaceutical industry, especially for personalised medicine.”.

Bürkert拥有将其集成到系统中的技术组件和专业知识。我们希望共同为制药行业，特别是个性化药物开发一个具有成本效益，可靠和可持续的生产平台。”。

The green transition forms a key part of the start-up’s vision – as manifested in the Green Elephant metaphor. Supporting large companies in the context of the green transition requires new approaches, courageous company founders and family businesses that want to make their contribution to the regenerative economy..

绿色过渡是初创企业愿景的关键部分，如“绿象”隐喻所示。在绿色转型的背景下支持大公司需要新的方法、勇敢的公司创始人和希望为再生经济做出贡献的家族企业。。

https://www.bionity.com/en/news/1185574/buerkert-invests-in-start-up-green-elephant-biotech.html

EU Funds Stem Cell Technologies for Heart Repair – Eppendorf is Project Partner

欧盟资助干细胞技术用于心脏修复——Eppendorf是项目合作伙伴

Read news

阅读新闻